Why the study?
Inconclusive noninvasive tests complicate care in suspected CAD, but their prevalence and impact on management, outcomes, and costs are not well described.
Do inconclusive noninvasive test results lead to worse clinical outcomes, more subsequent testing, and higher costs compared to negative test results in stable patients with suspected CAD?
Do inconclusive noninvasive test results lead to worse clinical outcomes, more subsequent testing, and higher costs compared to negative test results in stable patients with suspected CAD?
Inconclusive noninvasive tests in stable suspected CAD are associated with increased downstream testing, higher costs, and worse clinical outcomes compared to negative tests.
May identify higher-risk patients after inconclusive tests; leaves open whether targeted strategies improve outcomes in suspected CAD.
Background: Inconclusive noninvasive tests complicate the care of patients with suspected coronary artery disease, but their prevalence and impact on management, outcomes, and costs are not well described. Methods: PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) patients were randomized to stress testing (n=4533) or computed tomographic angiography (CTA; n=4677). We assessed relationships between inconclusive results, subsequent testing, a composite outcome (death, myocardial infarction, or hospitalization for unstable angina), and healthcare expenditures. Results: Overall, 8.0% of tests were inconclusive (9.7% stress, 6.4% CTA). Compared with negative tests, inconclusive tests were more often referred to a second noninvasive test (stress: 14.6% versus 8.5%, odds ratio [OR], 1.91; CTA: 36.5% versus 8.4%, OR, 5.95; P <0.001) and catheterization (stress: 5.5% versus 2.4%, OR, 2.36; CTA: 23.4% versus 4.1%, OR, 6.49; P <0.001), and composite outcomes were higher for both inconclusive tests (stress: 3.7% versus 2.0%, hazard ratio, 1.81, P =0.034; CTA: 5.0% versus 2.2%, hazard ratio, 1.85; P =0.044) and positive tests (stress: 8.3% versus 2.0%, hazard ratio, 3.50; CTA: 9.2% versus 2.2%, hazard ratio, 3.66; P <0.001). Twenty-four–month costs were higher for inconclusive tests than negative tests by $2905 (stress) and $4030 (CTA). Conclusions: Among patients with stable chest pain undergoing a noninvasive test, inconclusive results occurred in 6% of CTA and 10% of stress tests. Compared with those with conclusive negative tests, individuals with inconclusive results more often underwent subsequent testing, had increased medical costs, and experienced worse outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.
No takes yet. Share an insight, caveat, or question.
Goyal et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: